Frontiers | Predicting Antibody and ACE2 Affinity for SARS-CoV-2 BA.2.86 and JN.1 with In Silico Protein Modeling and Docking

Abstract

The emergence of SARS-CoV-2 lineages derived from Omicron, including BA.2.86 (nicknamed “Pirola”) and its relative, JN.1, has raised concerns about their potential impact on public and personal health due to numerous novel mutations. Despite this, predicting their implications based solely on mutation counts proves challenging. Empirical evidence of JN.1’s increased immune evasion capacity in relation to previous variants is mixed. To improve predictions beyond what is possible based solely on mutation counts, we conducted extensive in silico analyses on the binding affinity between the RBD of different SARS-CoV-2 variants (Wuhan-Hu-1, BA.1/B.1.1.529, BA.2, XBB.1.5, BA.2.86, and JN.1) and neutralizing antibodies from vaccinated or infected individuals, as well as the human angiotensin-converting enzyme 2 (ACE2) receptor. We observed no statistically significant difference in binding affinity between BA.2.86 or JN.1 and other variants. Therefore, we conclude that the new SARS-CoV-2 variants have no pronounced immune escape or infection capacity compared to previous variants. However, minor reductions in binding affinity for both the antibodies and ACE2 were noted for JN.1. Future research in this area will benefit from increased structural analyses of memory B-cell derived antibodies and should emphasize the importance of choosing appropriate samples for in silico studies to assess protection provided by vaccination and infection. Moreover, the fitness benefits of genomic variation outside of the RBD of BA.2.86 and JN.1 need to be investigated. This research contributes to understanding the BA.2.86 and JN.1 variants’ potential impact on public health.